This post has expired! It was posted more than 90 days ago.
<- Back

133493 - HPV Vaccines: The Next Generation

  • : Online

A Category 2, 1 hour online case study based program on HPV Vaccines

Relevance to General Practice

Human papillomaviruses (HPVs) infect and replicate mainly within cutaneous and mucosal epithelial tissues. Approximately 40 HPV types infect the anogenital tract. 

“High-risk” (HR) or oncogenic HPV types, including types 16, 18, 31, 33, 35, 45, 52 and 58, are associated with the development of cancer. The majority of genital HPV infections are subclinical and resolve spontaneously within a 12 to 24 months. However, approximately 3% to 10% of HR-HPV infections persist resulting in cellular abnormalities, such as cervical intraepithelial neoplasia (CIN), that may eventually progress into cancer. Cervical cancer usually occurs 10 to 20 years after initial infection with HR-HPV types. 
HPV types 6 and 11, designated “low-risk” (LR), cause about 95% of genital warts and all cases of recurrent respiratory papillomatosis. 

Learning outcomes
  • Explain the current recommendations for HPV vaccination, and how vaccination has been beneficial in reducing transmission of HPV in Australia.
  • Describe the qualities of the new HPV vaccine formulation in terms of indications, safety, immunogenicity and dosing schedules including interchangeability
  • Identify patients who are at risk of contracting HPV, and make recommendations on vaccine eligibility, including for those who do not qualify for the vaccine
  • Recognise barriers to HPV vaccination and respond to questions or concerns about the vaccine, such as adverse events and tolerability
  • Delivery
    133493 - HPV Vaccines: The Next Generation
    Provider Type
    Education Provider
    1 hour
    Start Date
    End Date
    CPD Points
    1 hour
    Contact Phone
    Log in into view this field.